ASCO Lung Cancer Highlights, Part 11: Nintedanib with Second Line Chemotherapy for Advanced NSCLC (audio)
Science
Dr. Edward Garon, David Geffen School of Medicine at UCLA, discusses results in a trial that demonstrated a significant survival benefit with nintedanib combined with second line docetaxel in advanced lung adenocarcinoma.